Table 3

Cardioversion Strategies by Country as Reported in the Site Questionnaires
Total AUS BR FR DEU ITL NL POL ESP SWE UK
% (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N)
Frequencywait-and-seeapproach
never 17.9 (31/173) 12.5 (1/8) 20.0 (2/10) 12.0 (3/25) 4.6 (1/22) 0 0 20.0 (3/15) 34.7 (17/49) 0 28.6 (4/14)
sometimes 69.4 (120/173) 75.0 (6/8) 50.0 (5/10) 60.0 (15/25) 90.9 (20/22) 80.0 (8/10) 100 (6/6) 66.7 (10/15) 59.2 (29/49) 92.9 (13/14) 57.1 (8/14)
frequent 12.7 (22/173) 12.5 (1/8) 30.0 (3/10) 28.0 (7/25) 4.6 (1/22) 20.0 (2/10) 0 13.3 (2/15) 6.1 (3/49) 7.1 (1/14) 14.3 (2/14)
Frequency PCV
never 0.6 (1/173) 0 0 0 0 0 0 0 0 7.1 (1/14) 0
sometimes 37.6 (65/173) 50.0 (4/8) 20.0 (2/10) 32.0 (8/25) 68.2 (15/22) 40.0 (4/10) 50.0 (3/6) 20.0 (3/15) 14.3 (7/49) 85.7 (12/14) 50.0 (7/14)
frequent 61.8 (107/173) 50.0 (4/8) 80.0 (8/10) 68.0 (17/25) 31.8 (7/22) 60.0 (6/10) 50.0 (3/6) 80.0 (12/15) 85.7 (42/49) 7.1 (1/14) 50.0 (7/14)
Frequency ECV
never 0.6 (1/172) 0 0 0 0 10.0 (1/10) 0 0 0 0 0
sometimes 32.6 (56/172) 25.0 (2/8) 30.0 (3/10) 16.7 (4/24) 0 70.0 (7/10) 0 6.7 (1/15) 67.4 (33/49) 14.3 (2/14) 28.6 (4/14)
frequent 66.9 (115/172) 75.0 (6/8) 70.0 (7/10) 83.3 (20/24) 100 (22/22) 20.0 (2/10) 100 (6/6) 93.3 (14/15) 32.6 (16/49) 85.7 (12/14) 71.4 (10/14)
Preferred drugs for PCV*
Amiodarone 85.7 (150/175) 100 (8/8) 100 (10/10) 81.5 (22/27) 90.9 (20/22) 60.0 (6/10) 83.3 (5/6) 93.3 (14/15) 85.7 (42/49) 64.3 (9/14) 100 (14/14)
Beta-blocker 23.4 (41/175) 12.5 (1/8) 40.0 (4/10) 0 40.9 (9/22) 10.0 (1/10) 16.7 (1/6) 53.3 (8/15) 12.2 (6/49) 28.6 (4/14) 50.0 (7/14)
Dronedarone 8.6 (15/175) 0 0 0 45.5 (10/22) 0 0 0 0 21.4 (3/14) 14.3 (2/14)
Flecainide 60.6 (106/175) 75.0 (6/8) 0 33.3 (9/27) 81.8 (18/22) 60.0 (6/10) 100 (6/6) 0 91.8 (45/49) 35.7 (5/14) 78.6 (11/14)
Propafenone 26.9 (47/175) 0 70.0 (7/10) 3.7 (1/27) 27.3 (6/22) 80.0 (8/10) 0 80.0 (12/15) 20.4 (10/49) 7.1 (1/14) 14.3 (2/14)
Sotalol 12.0 (21/175) 75.0 (6/8) 20.0 (2/10) 0 0 10.0 (1/10) 33.3 (2/6) 26.7 (4/15) 2.0 (1/49) 7.1 (1/14) 28.6 (4/14)
Verapamil 6.3 (11/175) 12.5 (1/8) 10.0 (1/10) 0 0 10.0 (1/10) 0 13.3 (2/15) 8.2 (4/49) 0 14.3 (2/14)
Other 5.1 (9/175) 0 0 0 0 10.0 (1/10) 33.3 (2/6) 0 6.1 (3/49) 14.3 (2/14) 7.1 (1/14)
Preferred type of ECV
Mono 5.8 (10/173) 0 10.0 (1/10) 12.0 (3/25) 4.6 (1/22) 10.0 (1/10) 0 0 6.1 (3/49) 7.1 (1/14) 0
Biphasic 94.2 (163/173) 100 (8/8) 90.0 (9/10) 88.0 (22/25) 95.5 (21/22) 90.0 (9/10) 100 (6/6) 100 (15/15) 93.9 (46/49) 92.9 (13/14) 100 (14/14)
Preferred heart rate target with rate control:
80 beats per minute 72.5 (124/171) 100 (8/8) 40.0 (4/10) 87.5 (21/24) 95.5 (21/22) 90.0 (9/10) 66.7 (4/6) 86.7 (13/15) 55.1 (27/49) 57.1 (8/14) 69.2 (9/13)
110 beats per minute 25.1 (43/171) 0 60.0 (6/10) 12.5 (3/24) 4.5 (1/22) 10.0 (1//10) 33.3 (2/6) 13.3 (2/15) 36.7 (18/49) 42.9 (6/14) 30.8 (4/13)
median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR
n§ n n n n n n n n n n
No. ECVs/year 100 (50–200) 105 (90–200.5) 30 (9–70) 120 (85–200) 300 (150–500) 85 (15–200) 225 (115–300) 70 (40–120) 50 (24–126.5) 225 (80–280) 111(100–168)
n = 170 n = 8 n = 10 n = 23 n = 22 n = 10 n = 6 n = 15 n = 48 n = 14 n = 14

No. PCVs/

year

100 (37.5-200) 102 (32.5-185) 50 (20–80) 150 (30–200) 60 (25–100) 175 (100–250) 108 (50–200) 150 (40–250) 121 (98–300) 15 (4–30) 68 (30–140)
n = 168 n = 8 n = 9 n = 22 n = 21 n = 10 n = 6 n = 15 n = 48 n = 14 n = 14
Number of ablation procedures (among those performing ablations) 156 (53–300) 46 (35–179) 64 (20–180) 300 (112–450) 300 (155–400) 210 (120–480) 440 (279–669) 105 (53–171) 125 (40–188) 250 (120–856) 35 (19–88)
n = 112 n = 6 n = 10 n = 19 n = 18 n = 6 n = 4 n = 12 n = 29 n = 3 n = 5

PCV, pharmacologic cardioversion; ECV, electrical cardioversion.

*Preferred drugs for PCV- sites had the option to choose one or more of drug options given, in addition to other.

†Other does not include bepridil, cibenzoline, cordichin, moricizine, tocainide which were “0” for all.

‡ ≤ 110 beats per minute: bpm: > 80 and ≤ 110.

§n = number of sites.

Crijns et al.

Crijns et al. BMC Cardiovascular Disorders 2012 12:85   doi:10.1186/1471-2261-12-85

Open Data